Bullet points of Feds sue pharmacy gatekeepers over high insulin costs

Bullet points of Feds sue pharmacy gatekeepers over high insulin costs
- The FTC claims that the companies created a perverse drug rebate system favoring high rebates from drugmakers, spurring them to artificially inflate their products' list prices.
- The companies would exclude low-cost insulins from their drug formularies in favor of the higher-priced options.
- The FTC official said the goal is to change drug pricing practices across the pharmaceutical market.